The Experts below are selected from a list of 12567 Experts worldwide ranked by ideXlab platform

Michael Amon - One of the best experts on this subject based on the ideXlab platform.

  • REVIEW Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for Postoperative anti-inflammatory use
    2016
    Co-Authors: Michael Amon, Massimo Busin
    Abstract:

    Abstract Topical corticosteroids are routinely used as Postoperative ocular anti-inflammatory drugs; how-ever, adverse effects such as increased intraocular pressure (IOP) are observed with their use. While older corticosteroids such as dexamethasone and predniso-lone acetate offer good anti-inflammatory efficacy, clinically significant increases in IOP (C10 mmHg) are often associated with their use. Loteprednol eta-bonate, a novel C-20 ester-based corticosteroid, was retrometabolically designed to offer potent anti-inflammatory efficacy but with decreased impact on IOP. After exerting its therapeutic effects on the site of action, loteprednol etabonate is rapidly converted to inactive metabolites, resulting in fewer adverse effects. Randomized controlled studies have demonstrated the clinical efficacy and safety of loteprednol etabonate ophthalmic suspension 0.5 % for the treatment of Postoperative Inflammation in post-cataract patients with few patients, if any, exhibiting clinically signif-icant increases (C10 mmHg) in IOP. Furthermore, safety studies demonstrated a minimal effect of loteprednol etabonate on IOP with long-term use or in steroid responders with a much lower propensity to increase IOP relative to prednisolone acetate or dexamethasone. The anti-inflammatory treatment effect of loteprednol etabonate appears to be similar to that of rimexolone and difluprednate with less impact on IOP compared to difluprednate, although confirmatory comparative studies are needed. The available clinical data suggest that loteprednol etabon-ate is an efficacious and safe corticosteroid for the treatment of Postoperative Inflammation

  • loteprednol etabonate ophthalmic suspension 0 5 efficacy and safety for Postoperative anti inflammatory use
    International Ophthalmology, 2012
    Co-Authors: Michael Amon, Massimo Busin
    Abstract:

    Topical corticosteroids are routinely used as Postoperative ocular anti-inflammatory drugs; however, adverse effects such as increased intraocular pressure (IOP) are observed with their use. While older corticosteroids such as dexamethasone and prednisolone acetate offer good anti-inflammatory efficacy, clinically significant increases in IOP (≥10 mmHg) are often associated with their use. Loteprednol etabonate, a novel C-20 ester-based corticosteroid, was retrometabolically designed to offer potent anti-inflammatory efficacy but with decreased impact on IOP. After exerting its therapeutic effects on the site of action, loteprednol etabonate is rapidly converted to inactive metabolites, resulting in fewer adverse effects. Randomized controlled studies have demonstrated the clinical efficacy and safety of loteprednol etabonate ophthalmic suspension 0.5 % for the treatment of Postoperative Inflammation in post-cataract patients with few patients, if any, exhibiting clinically significant increases (≥10 mmHg) in IOP. Furthermore, safety studies demonstrated a minimal effect of loteprednol etabonate on IOP with long-term use or in steroid responders with a much lower propensity to increase IOP relative to prednisolone acetate or dexamethasone. The anti-inflammatory treatment effect of loteprednol etabonate appears to be similar to that of rimexolone and difluprednate with less impact on IOP compared to difluprednate, although confirmatory comparative studies are needed. The available clinical data suggest that loteprednol etabonate is an efficacious and safe corticosteroid for the treatment of Postoperative Inflammation.

  • effect of heparin in the irrigation solution on Postoperative Inflammation and cellular reaction on the intraocular lens surface
    Journal of Cataract and Refractive Surgery, 2002
    Co-Authors: Andreas Kruger, Michael Amon, Gebtraud Schild, Julia Kolodjaschna, Claudette Abelaformanek, Jörg Schauersberger
    Abstract:

    Abstract Purpose: To evaluate the influence of heparin sodium in the irrigation solution on Postoperative Inflammation and cellular reaction on the anterior surface of a hydrophilic intraocular lens (IOL). Setting: Department of Ophthalmology, University of Vienna, Vienna, Austria. Methods: This randomized prospective single-surgeon study included 50 patients with senile cataract only. Half the patients received 1 mL of heparin sodium (concentration 10 IU/mL) in addition to the regular irrigating solution. In all other respects, the procedure was standardized: clear corneal incision, phacoemulsification, and implantation of a Hydroview® foldable hydrogel IOL (Bausch & Lomb). The parameters of Inflammation—anterior chamber flare and cells—were evaluated with the pupil dilated in a masked fashion using a Kowa FC-1000 laser flare-cell meter 1, 3, 7, 14, and 28 days and 3, 6 and 12 months Postoperatively. The cellular reaction was semiquantitatively examined and analyzed by specular microscopy. Results: In both groups, flare and cell values increased on the first Postoperative day and successively decreased thereafter. In the first week, the flare and cell values were significantly higher in the group without heparin sodium in the irrigating solution. Subsequently, there were no differences between the 2 groups in flare or cells. At 1 day, the heparin sodium group had statistically significantly fewer IOLs with no cells on the surface. Subsequently, no differences in cellular reaction on the IOL were observed. Conclusions: Heparin sodium added to the standard irrigating solution reduced disturbances of the blood-aqueous barrier in the early Postoperative period. There seemed to be no long-term effect, especially on cellular reaction, on the hydrophilic IOL surface.

Massimo Busin - One of the best experts on this subject based on the ideXlab platform.

  • REVIEW Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for Postoperative anti-inflammatory use
    2016
    Co-Authors: Michael Amon, Massimo Busin
    Abstract:

    Abstract Topical corticosteroids are routinely used as Postoperative ocular anti-inflammatory drugs; how-ever, adverse effects such as increased intraocular pressure (IOP) are observed with their use. While older corticosteroids such as dexamethasone and predniso-lone acetate offer good anti-inflammatory efficacy, clinically significant increases in IOP (C10 mmHg) are often associated with their use. Loteprednol eta-bonate, a novel C-20 ester-based corticosteroid, was retrometabolically designed to offer potent anti-inflammatory efficacy but with decreased impact on IOP. After exerting its therapeutic effects on the site of action, loteprednol etabonate is rapidly converted to inactive metabolites, resulting in fewer adverse effects. Randomized controlled studies have demonstrated the clinical efficacy and safety of loteprednol etabonate ophthalmic suspension 0.5 % for the treatment of Postoperative Inflammation in post-cataract patients with few patients, if any, exhibiting clinically signif-icant increases (C10 mmHg) in IOP. Furthermore, safety studies demonstrated a minimal effect of loteprednol etabonate on IOP with long-term use or in steroid responders with a much lower propensity to increase IOP relative to prednisolone acetate or dexamethasone. The anti-inflammatory treatment effect of loteprednol etabonate appears to be similar to that of rimexolone and difluprednate with less impact on IOP compared to difluprednate, although confirmatory comparative studies are needed. The available clinical data suggest that loteprednol etabon-ate is an efficacious and safe corticosteroid for the treatment of Postoperative Inflammation

  • loteprednol etabonate ophthalmic suspension 0 5 efficacy and safety for Postoperative anti inflammatory use
    International Ophthalmology, 2012
    Co-Authors: Michael Amon, Massimo Busin
    Abstract:

    Topical corticosteroids are routinely used as Postoperative ocular anti-inflammatory drugs; however, adverse effects such as increased intraocular pressure (IOP) are observed with their use. While older corticosteroids such as dexamethasone and prednisolone acetate offer good anti-inflammatory efficacy, clinically significant increases in IOP (≥10 mmHg) are often associated with their use. Loteprednol etabonate, a novel C-20 ester-based corticosteroid, was retrometabolically designed to offer potent anti-inflammatory efficacy but with decreased impact on IOP. After exerting its therapeutic effects on the site of action, loteprednol etabonate is rapidly converted to inactive metabolites, resulting in fewer adverse effects. Randomized controlled studies have demonstrated the clinical efficacy and safety of loteprednol etabonate ophthalmic suspension 0.5 % for the treatment of Postoperative Inflammation in post-cataract patients with few patients, if any, exhibiting clinically significant increases (≥10 mmHg) in IOP. Furthermore, safety studies demonstrated a minimal effect of loteprednol etabonate on IOP with long-term use or in steroid responders with a much lower propensity to increase IOP relative to prednisolone acetate or dexamethasone. The anti-inflammatory treatment effect of loteprednol etabonate appears to be similar to that of rimexolone and difluprednate with less impact on IOP compared to difluprednate, although confirmatory comparative studies are needed. The available clinical data suggest that loteprednol etabonate is an efficacious and safe corticosteroid for the treatment of Postoperative Inflammation.

Raymond Fong - One of the best experts on this subject based on the ideXlab platform.

  • submicron loteprednol etabonate ophthalmic gel 0 38 for the treatment of Inflammation and pain after cataract surgery
    Journal of Cataract and Refractive Surgery, 2018
    Co-Authors: Raymond Fong, Bruce E Silverstein, James H Peace, Jon I Williams, Jason L Vittitow
    Abstract:

    Purpose To assess the safety and efficacy of a 0.38% submicron formulation of loteprednol etabonate (LE) gel for the treatment of Postoperative Inflammation and pain after cataract surgery. Setting Forty-five United States ophthalmology practices. Design Double-masked vehicle-controlled randomized parallel group study. Methods Patients 18 years of age or older with anterior chamber cells grade 2 or higher on day 1 after uncomplicated cataract surgery were randomized to 14 days of treatment with LE gel 2 times a day, LE gel 3 times a day, or vehicle. Hierarchical primary endpoints were the proportion of patients with resolution of anterior chamber cells and grade 0 (no) pain at Postoperative day 8. Safety outcomes included adverse events, intraocular pressure (IOP), biomicroscopy, visual acuity, ophthalmoscopy, and tolerability (drop comfort and ocular symptoms). Results The intent-to-treat population included 514 patients. Significantly more patients in the LE gel 2 times a day and 3 times a day groups compared with the vehicle group had complete resolution of anterior chamber cells (26.9% and 28.7% versus 9.3%) and reported grade 0 pain (73.7% and 73.1% versus 47.7%) on day 8 (P  Conclusion In this study, submicron loteprednol etabonate gel 0.38% appeared safe and effective in the treatment of Postoperative Inflammation and pain whether instilled 2 times or 3 times a day.

  • loteprednol etabonate ophthalmic gel 0 5 following cataract surgery integrated analysis of two clinical studies
    Advances in Therapy, 2013
    Co-Authors: Rajesh K Rajpal, Raymond Fong, Timothy L Comstock
    Abstract:

    Introduction We aimed to evaluate the safety and efficacy of loteprednol etabonate (LE) gel 0.5% compared with vehicle in the treatment of Postoperative Inflammation and pain following cataract surgery, using the integrated analysis of data from two identical, prospective, multicenter, randomized, double-masked, parallel-group, vehicle-controlled trials.

Jason L Vittitow - One of the best experts on this subject based on the ideXlab platform.

  • submicron loteprednol etabonate ophthalmic gel 0 38 for the treatment of Inflammation and pain after cataract surgery
    Journal of Cataract and Refractive Surgery, 2018
    Co-Authors: Raymond Fong, Bruce E Silverstein, James H Peace, Jon I Williams, Jason L Vittitow
    Abstract:

    Purpose To assess the safety and efficacy of a 0.38% submicron formulation of loteprednol etabonate (LE) gel for the treatment of Postoperative Inflammation and pain after cataract surgery. Setting Forty-five United States ophthalmology practices. Design Double-masked vehicle-controlled randomized parallel group study. Methods Patients 18 years of age or older with anterior chamber cells grade 2 or higher on day 1 after uncomplicated cataract surgery were randomized to 14 days of treatment with LE gel 2 times a day, LE gel 3 times a day, or vehicle. Hierarchical primary endpoints were the proportion of patients with resolution of anterior chamber cells and grade 0 (no) pain at Postoperative day 8. Safety outcomes included adverse events, intraocular pressure (IOP), biomicroscopy, visual acuity, ophthalmoscopy, and tolerability (drop comfort and ocular symptoms). Results The intent-to-treat population included 514 patients. Significantly more patients in the LE gel 2 times a day and 3 times a day groups compared with the vehicle group had complete resolution of anterior chamber cells (26.9% and 28.7% versus 9.3%) and reported grade 0 pain (73.7% and 73.1% versus 47.7%) on day 8 (P  Conclusion In this study, submicron loteprednol etabonate gel 0.38% appeared safe and effective in the treatment of Postoperative Inflammation and pain whether instilled 2 times or 3 times a day.

Timothy L Comstock - One of the best experts on this subject based on the ideXlab platform.